Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.97 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.97 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.97 |
| ▸ | MEN1 | O00255 | 1/20 | 0.97 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.97 |
| ▸ | DGKA | P23743 | 1/20 | 0.80 |
| ▸ | FAAH | O00519 | 2/20 | 0.67 |
| ▸ | MAPT | P10636 | 1/20 | 0.67 |
| ▸ | PRKCA | P17252 | 3/20 | 0.64 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.64 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.64 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.64 |
| ▸ | ENPP2 | Q13822 | 4/20 | 0.63 |
| ▸ | LPAR6 | P43657 | 1/20 | 0.63 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.63 |
| ▸ | LPAR4 | Q99677 | 1/20 | 0.63 |
| ▸ | LPAR5 | Q9H1C0 | 1/20 | 0.63 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.63 |
| ▸ | LPAR3 | Q9UBY5 | 1/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Monoctanoin Component A SCHEMBL8808728 | 1.00 | LMNA (0.97) | LMNAKDM4EDUSP3MEN1KMT2A | |
| Glycerin SCHEMBL17975822 | 1.00 | LMNA (0.97) | LMNAKDM4EDUSP3MEN1KMT2A | |
| Glycerin SCHEMBL2363511 | 1.00 | LMNA (0.97) | LMNAKDM4EDUSP3MEN1KMT2A | |
| Monoctanoin Component A SCHEMBL28134044 | 1.00 | LMNA (0.97) | LMNAKDM4EDUSP3MEN1KMT2A | |
| Glyceryl Monostearate SCHEMBL7608785 | 1.00 | LMNA (0.97) | LMNAKDM4EDUSP3MEN1KMT2A | |
| Glycerol Monolaurate SCHEMBL12230991 | 1.00 | LMNA (0.97) | LMNAKDM4EDUSP3MEN1KMT2A | |
| Glycerin SCHEMBL3720558 | 1.00 | LMNA (0.97) | LMNAKDM4EDUSP3MEN1KMT2A | |
| Glycerol Monopalmitate SCHEMBL977143 | 0.98 | LMNA (1.00) | LMNAKDM4EDUSP3MEN1KMT2A | |
| SCHEMBL2119138 | 0.98 | LMNA (1.00) | LMNAKDM4EDUSP3MEN1KMT2A | |
| SCHEMBL10937708 | 0.98 | LMNA (1.00) | LMNAKDM4EDUSP3MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1528917-B1 | DOSAGE FORM COMPRISING HIGH DOSE HIGH SOLUBLE ACTIVE INGREDIENT AS MODIFIED RELEASE AND LOW DOSE ACTIVE INGREDIENT AS IMMEDIATE RELEASE | TORRENT PHARMACEUTICALS LTD (IN) | 2013-06-19 | — | — | EP | claimed |
| US-8263125-B2 | Dosage form for high dose-high solubility active ingredients that provides for immediate release and modified release of the active ingredients | TORRENT PHARMACEUTICALS LIMITED (IN) | 2012-09-11 | — | — | US | claimed |
| US-20060153916-A1 | Novel dosage form | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-07-13 | — | — | US | claimed |
| US-20060024365-A1 | Novel dosage form | VAYA NAVIN | 2006-02-02 | — | — | US | claimed |
| WO-2005065639-A2 | NOVEL PHARMACEUTICAL COMPOSITIONS | TORRENT PHARMACEUTICALS LIMITED (IN) | 2005-07-21 | — | — | WO | claimed |
| EP-1528917-A2 | DOSAGE FORM COMPRISING HIGH DOSE HIGH SOLUBLE ACTIVE INGREDIENT AS MODIFIED RELEASE AND LOW DOSE ACTIVE INGREDIENT AS IMMEDIATE RELEASE | Torrent Pharmaceuticals Ltd (IN) | 2005-05-11 | — | — | EP | claimed |
| US-20040096499-A1 | Novel dosage form | TORRENT PHARMACEUTICALS LIMITED (IN) | 2004-05-20 | — | — | US | claimed |
| WO-2004012700-A2 | DOSAGE FORM COMPRISING HIGH DOSE HIGH SOLUBLE ACTIVE INGREDIENT AS MODIFIED RELEASE AND LOW DOSE ACTIVE INGREDIENT AS IMMEDIATE RELEASE | TORRENT PHARMACEUTICALS LIMITED (IN) | 2004-02-12 | — | — | WO | claimed |
| CN-105007947-B | solid solution compositions and their use in cardiovascular disease | 因佛斯特医疗有限公司 | 2019-02-15 | — | — | CN | disclosed |
| US-10016393-B2 | Stabilized pharmaceutical dosage forms comprising atrasentan | ABBVIE INC. (US) | 2018-07-10 | — | — | US | disclosed |
| CN-104968368-B | Solid solution compositions and their use in severe pain | 因佛斯特医疗有限公司 | 2018-05-04 | — | — | CN | disclosed |
| US-20160250186-A1 | STABILIZED PHARMACEUTICAL DOSAGE FORMS COMPRISING ATRASENTAN | ABBVIE INC. | 2016-09-01 | — | — | US | disclosed |
| US-9364458-B2 | Stabilized pharmaceutical dosage forms comprising atrasentan | ABBVIE INC. (US) | 2016-06-14 | — | — | US | disclosed |
| US-20150011602-A1 | STABILIZED PHARMACEUTICAL DOSAGE FORMS COMPRISING ATRASENTAN | ABBVIE INC. (US) | 2015-01-08 | — | — | US | disclosed |
| CN-102007211-B | Buttiauxella sp. phytase variants | DANISCO US INC | 2013-11-06 | — | — | CN | disclosed |
| CN-102007211-A | Buttiauxella sp. phytase variants | DANISCO US INC | 2011-04-06 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160250186-A1 | STABILIZED PHARMACEUTICAL DOSAGE FORMS COMPRISING ATRASENTAN | AGTR2, REN, SLC5A2 | LMNA 3871/4885KDM4E 4719/4885DUSP3 4034/4885 |
| US-20150011602-A1 | STABILIZED PHARMACEUTICAL DOSAGE FORMS COMPRISING ATRASENTAN | REN, AGTR1, ATP6V1B1 | LMNA 3331/4885KDM4E 4359/4885DUSP3 4103/4885 |
| US-10016393-B2 | Stabilized pharmaceutical dosage forms comprising atrasentan | AGTR2, REN, SLC5A2 | LMNA 3871/4885KDM4E 4719/4885DUSP3 4034/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.